ING Groep NV purchased a new stake in Global Blood Therapeutics Inc (NASDAQ:GBT) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 136,175 shares of the company’s stock, valued at approximately $5,358,000.

Several other large investors have also recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its holdings in shares of Global Blood Therapeutics by 12.6% in the 4th quarter. Alps Advisors Inc. now owns 48,423 shares of the company’s stock valued at $1,905,000 after buying an additional 5,408 shares in the last quarter. Taylor Wealth Management Partners boosted its holdings in shares of Global Blood Therapeutics by 2.7% in the 4th quarter. Taylor Wealth Management Partners now owns 48,865 shares of the company’s stock valued at $1,923,000 after buying an additional 1,300 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in Global Blood Therapeutics in the 4th quarter worth approximately $713,000. Fiduciary Trust Co. boosted its stake in Global Blood Therapeutics by 17.1% in the 4th quarter. Fiduciary Trust Co. now owns 27,604 shares of the company’s stock worth $1,086,000 after purchasing an additional 4,024 shares in the last quarter. Finally, GW&K Investment Management LLC boosted its stake in Global Blood Therapeutics by 41.2% in the 4th quarter. GW&K Investment Management LLC now owns 145,717 shares of the company’s stock worth $5,734,000 after purchasing an additional 42,519 shares in the last quarter. Institutional investors and hedge funds own 85.67% of the company’s stock.

Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) opened at $59.00 on Friday. Global Blood Therapeutics Inc has a 12 month low of $17.70 and a 12 month high of $65.40. The company has a market cap of $2,827.15, a P/E ratio of -23.14 and a beta of 4.78.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same quarter last year, the business posted ($0.58) EPS. research analysts forecast that Global Blood Therapeutics Inc will post -2.53 EPS for the current year.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $36.55, for a total transaction of $109,650.00. Following the completion of the sale, the insider now directly owns 135,255 shares in the company, valued at approximately $4,943,570.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Peter Radovich sold 812 shares of Global Blood Therapeutics stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $57.30, for a total transaction of $46,527.60. Following the sale, the insider now owns 6,221 shares of the company’s stock, valued at $356,463.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,812 shares of company stock valued at $2,864,728. Company insiders own 5.30% of the company’s stock.

A number of analysts recently commented on the stock. Oppenheimer set a $53.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine cut shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub upgraded shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 1st. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, William Blair assumed coverage on shares of Global Blood Therapeutics in a research note on Tuesday, January 23rd. They issued an “outperform” rating and a $80.00 target price for the company. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $63.27.

WARNING: This article was reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2018/02/09/ing-groep-nv-purchases-new-holdings-in-global-blood-therapeutics-inc-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.